Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biomedical Engineering
Vista Partners Updates Coverage on Inovio Biomedical Corporation
April 11th, 2007
Vista Partners announced that it has updated coverage on Inovio Biomedical Corporation (AMEX:INO). Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. Ross Silver of Vista Partners issued the report. For more information and to download the report, please visit the Vista Partners website at www.vistap.com. Inovio Biomedical is focused on commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA vaccines using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors...
Source: Medical Patent Law Weekly (2007-04-11)
|
